絞り込み

16535

広告

チーム医療で男子生徒救助 後遺症なし (毎日新聞)

男子生徒を救助したドクターヘリと小倉真治センター長=岐阜大医学部付属病院提供 [PR] 当時の状況を説明する(右から)楠沢さん、小倉センター長、長藤さん=岐阜市...

  1. [医学] 調べたナルコレプシー患者全員が...
  2. 働きやすい環境工夫 静岡の民間企業 - ...
  3. 焦点:グリーンランドの巨大氷河崩壊、温暖...
  4. 【J1ピックアッププレビュー】同じDNA...

ニュース一覧

Antithrombotic therapy for venous thromboembolism in patients with cancer: expert guidance.

著者 Imberti D , Cimminiello C , di Nisio M , Marietta M , Polo Friz H , Ageno W
Expert Opin Pharmacother.2018 Jul 02 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (35view , 0users)

Full Text Sources

Miscellaneous

Most of the current clinical guidelines recommend the use of Low Molecular Weight Heparins (LMWHs) for cancer-associated thrombosis (CAT). The Hokusai VTE-cancer trial reported the first results of a direct comparison between a direct oral anticoagulant (DOAC), edoxaban, and LMWH in this setting. Areas covered: This review aims to critically appraise the currently available evidence on the efficacy and safety of anticoagulant agents for the long-term treatment of CAT and to provide an expert opinion and guidance in this field. Expert opinion: Based on the available evidence, DOACs represent a valid alternative to LMWH for the treatment of CAT for the majority of patients with active cancer. Currently, most solid evidence comes from the HOKUSAI-VTE cancer study, which showed that edoxaban is non-inferior to the LMWH dalteparin, with a trend toward fewer recurrent venous thromboembolic events, but with more major bleeding events. Similar findings were reported with rivaroxaban, although the study was not sufficiently powered to allow definitive conclusions. The majority of bleeding events occurred in the upper gastrointestinal tract and in patients with gastrointestinal cancer. Thus, LMWH remains the preferred option for patients with gastrointestinal cancer. Additional studies aimed to confirm these findings with other DOACs are now warranted.
PMID: 29963962 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード